CardiacSense

CardiacSense
CardiacSense develops a CE and FDA-cleared medical watch for continuous cardiac monitoring and arrhythmia detection.
About
Technology stack
detected 2026-06-27“The CardiacSense patent settlement. Cirqa as a Whoop competitor. Each one of those is Garmin responding to something specific.”
View on Reddit“I am interested in a long term monitor. Desired features: Continuous HR monitoring and record retention for 7-30 days. afib event detection. Wireless charging while wearing, similar to whoop, or at least several days of battery life. Either…”
View on Reddit“CardiacSense Ltd. CS System 3 is a wristworn medical device that measures heart rate, Pulse Rate and detects atrial fibrillation (AFib) by reading the users PPG and ECG CS322 (2A4CTCS322).”
View on Reddit“I'm aware that Zio and a few other companies are working on continuous-monitoring watches but stumbled onto this one today. Anyone else know anything about it? https://www.cardiacsense.com/heart-rate-monitor-watch/ Their plans for next year…”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.
What does CardiacSense do?
CardiacSense is revolutionizing healthcare with its cutting-edge medical watch designed for continuous cardiac monitoring. The CE and FDA-cleared device boasts high sensitivity and specificity in detecting A-Fib and various arrhythmias using PPG and/or ECG technology, providing valuable insights for patients and healthcare providers.
How much funding has CardiacSense raised?
CardiacSense has raised a total of $11M in funding.
Where is CardiacSense headquartered?
CardiacSense is headquartered in Tel Aviv, Israel.
When was CardiacSense founded?
CardiacSense was founded in 2009.
What industry does CardiacSense operate in?
CardiacSense operates in Healthcare, Digital Health, Sensor, Wearable, Heart Rate, Blood Pressure.
How many employees does CardiacSense have?
CardiacSense has approximately 39 people on record.
